On the regulation and control of fibrinolysis
Retatrutide is still in the middle of its phase 3 trial program
For those who prefer non-invasive treatments, capsules provide a needle-free option that is easy to incorporate into daily life
Eisai's Approach to U.S
(5)Fmoc-Asp(otBu)-Ala-Gly-Leu-Val- (5) Preparation of Fmoc-Asp(otBu)-Ala-Gly-Leu-Val-resin: (4)Fmoc-Ala-Gly-Leu-Val-1050530105010603DMF3DMF2DMFFmoc-Asp(otBu)-OHDIEATBTU/HOBtHBTU/HOBtBOP/HOBt105010603DMF3DMF2Fmoc-Asp(otBu)-Ala-Gly-Leu-Val- In the Fmoc-Ala-Gly-Leu-Val-resin in step (4), add the decapping reagent at 10-50C and react for 5-30 minutes, dry it with a vacuum pump, and add the decapping reagent again at 10-50C for 10-60 minutes , drained, washed 3 times with isopropanol, 3 times with DMF, 2 times with re-distilled DMF, added Fmoc-Asp(otBu)-OH, DIEA, TBTU/HOBt or HBTU/HOBt dissolved in DMF or The mixture of BOP/HOBt was reacted at 10-50C for 10-60 minutes, dried by vacuum pump, washed 3 times with isopropanol, washed 3 times with DMF, washed 2 times with re-distilled DMF, and dried to obtain Fmoc-Asp (otBu)-Ala-Gly-Leu-Val-resin